TG Therapeutics reported $1.59B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Alaunos Therapeutics USD 1.52M 367K Jun/2026
Amgen USD 96.05B 409M Sep/2026
Ardelyx USD 587.52M 11.63M Sep/2026
Arrowhead Research USD 1.74B 373.76M Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Curis USD 29.69M 9.72M Mar/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Novavax USD 888M 67.57M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
TG Therapeutics USD 1.59B 47.38M Sep/2026
Verastem USD 227.81M 18.63M Mar/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026